MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00083305" target="_blank" >RIV/00216224:14110/15:00083305 - isvavai.cz</a>
Result on the web
<a href="http://www.ashjournal.com/article/S1933-1711(14)00909-7/abstract" target="_blank" >http://www.ashjournal.com/article/S1933-1711(14)00909-7/abstract</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jash.2014.12.011" target="_blank" >10.1016/j.jash.2014.12.011</a>

Result language
angličtina
Original language name
MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment
Original language description
Pulmonary arterial hypertension (PAH) is a severe and increasingly prevalent disease, manifested by the maladaptation of pulmonary vasculature, which consequently leads to right heart failure and possibly even death. The development of PAH is characterized by specific functional as well as structural changes, primarily associated with the aberrant function of the pulmonary artery endothelial cells, smooth muscle cells, and vascular fibroblasts. MicroRNAs constitute a class of small 22?nucleotides?long non?coding RNAs that post?transcriptionally regulate gene expression and that may lead to significant cell proteome changes. While the involvement of miRNAs in the development of various diseases?especially cancer?has been reported, numerous miRNAs have also been associated with PAH onset, progression, or treatment responsiveness.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)